Translational stem cell therapy for amyotrophic lateral sclerosis

被引：0
|
作者：
Nicholas M. Boulis
Thais Federici
Jonathan D. Glass
J. Simon Lunn
Stacey A. Sakowski
Eva L. Feldman
机构：
[1] Emory University,Department of Neurosurgery
[2] Emory University,Department of Neurology
[3] University of Michigan,Department of Neurology
来源：
Nature Reviews Neurology | 2012年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The first-in-human phase I trial of stem cell transplantation for amyotrophic lateral sclerosis was approved by the FDA in 2009 and is ongoing. In their Perspectives article, Eva Feldman and colleagues, who are conducting the trial, discuss the preclinical research supporting this therapeutic approach, key aspects of the trial design to overcome translational issues, and ongoing challenges to address in future studies.
引用
收藏
页码：172 / 176
页数：4
相关论文
共 50 条
  • [31] Advancing Stem Cell Therapy for Repair of Damaged Lung Microvasculature in Amyotrophic Lateral Sclerosis
    Garbuzova-Davis, Svitlana
    Shell, Robert
    Mustafa, Hilmi
    Hailu, Surafuale
    Willing, Alison E.
    Sanberg, Paul R.
    Borlongan, Cesario, V
    CELL TRANSPLANTATION, 2020, 29
  • [32] Human Neural Stem Cell Replacement Therapy for Amyotrophic Lateral Sclerosis by Spinal Transplantation
    Hefferan, Michael P.
    Galik, Jan
    Kakinohana, Osamu
    Sekerkova, Gabriela
    Santucci, Camila
    Marsala, Silvia
    Navarro, Roman
    Hruska-Plochan, Marian
    Johe, Karl
    Feldman, Eva
    Cleveland, Don W.
    Marsala, Martin
    PLOS ONE, 2012, 7 (08):
  • [33] Cell therapy in amyotrophic lateral sclerosis: science and controversy
    Galan, L.
    Guerrero-Sola, A.
    Gomez-Pinedo, U.
    Matias-Guiu, J.
    NEUROLOGIA, 2010, 25 (08): : 467 - 469
  • [34] Translational challenges in amyotrophic lateral sclerosis therapy with macrophage migration inhibitory factor
    Alfahel, Leenor
    Rajkovic, Aleksandar
    Israelson, Adrian
    NEURAL REGENERATION RESEARCH, 2025, 20 (09) : 2583 - 2584
  • [35] Translational challenges in amyotrophic lateral sclerosis therapy with macrophage migration inhibitory factor
    Leenor Alfahel
    Aleksandar Rajkovic
    Adrian Israelson
    Neural Regeneration Research, 2025, 20 (09) : 2583 - 2584
  • [36] Clinical relevance of stem cell therapies in amyotrophic lateral sclerosis
    Srivastava, Amit K.
    NEUROLOGY INDIA, 2014, 62 (03) : 239 - 248
  • [37] Autologous Mesenchymal Stem Cell (MSC) Therapy for Amyotrophic Lateral Sclerosis (ALS): Preclinical Studies
    Staff, Nathan P.
    Chen, Bingkun
    Knight, Andrew M.
    Padley, Douglas J.
    Gastineau, Dennis A.
    Sorenson, Eric J.
    Dietz, Allan B.
    Windebank, Anthony J.
    ANNALS OF NEUROLOGY, 2009, 66 : S22 - S22
  • [38] Systemic Dental Pulp Stem Cell Secretome Therapy in a Mouse Model of Amyotrophic Lateral Sclerosis
    Wang, Junmei
    Zuzzio, Kirstin
    Walker, Chandler L.
    BRAIN SCIENCES, 2019, 9 (07)
  • [39] INDUCED PLURIPOTENT STEM CELLS IN MODELING AND CELL-BASED THERAPY OF AMYOTROPHIC LATERAL SCLEROSIS
    Csobonyeiova, M.
    Polak, S.
    Nicodemou, A.
    Danisovic, L.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2017, 68 (05): : 649 - 657
  • [40] INTRATHECAL AUTOLOGOUS BONE MARROW DERIVED MESENCHYMAL STEM CELL THERAPY FOR AMYOTROPHIC LATERAL SCLEROSIS
    Gabri, H.
    Kishk, N.
    Belal, E.
    Aboelfotooh, A.
    M, E.
    CYTOTHERAPY, 2017, 19 (05) : S121 - S122
12345